Minguet J, Sims HM, Smith KH, et al. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2016:1–11.
http://dx.doi.org/10.1080/17512433.2016.1258301
When the above article was first published online, the “Declaration of interest” section omitted author information. This has now been corrected in the online and print versions, and the full declaration of interest has been provided below.
Peter Bramlage provided consultancy to and received research funding from Daiichi Sankyo. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.